Multiple Myeloma
FDA Approves Johnson & Johnson’s New Multiple Myeloma Therapy
FDA approval, Johnson & Johnson, multiple myeloma, CAR-T cell therapy, bispecific antibody, TALVEY, CARVYKTI, DARALEXASPRO
J&J, Legend’s Phase III Win Cements Carvykti as Earlier-Line Multiple Myeloma Treatment
Carvykti, Multiple Myeloma, Phase III, CARTITUDE-4, FDA Approval, BCMA-Targeted Therapy, Johnson & Johnson, Legend Biotech
Sanofi’s Sarclisa Achieves First-in-Class Win, Poised to Surpass J&J in Multiple Myeloma Treatment
Sarclisa, Sanofi, multiple myeloma, J&J, ASCO, IMROZ study, anti-CD38 therapy, VRd, transplant-ineligible patients
GSK Strengthens Case for Blenrep’s Return in Multiple Myeloma Treatment
Blenrep, GSK, multiple myeloma, ASCO, DREAMM-8, DREAMM-7, Velcade, Darzalex, Pomalyst, CAR-T therapy, antibody-drug conjugate
GSK details Blenreps PhIII combo winas it hopes to stage a turnaround in multiple myeloma
Multiple Myeloma, Blenrep, turnaround, GSK’s, Progression-Free Survival, Combined